Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

ClinicalTrials.gov ID: NCT03005782

Public ClinicalTrials.gov record NCT03005782. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 13, 2026, 6:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies

Study identification

NCT ID
NCT03005782
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
333 participants

Conditions and interventions

Conditions

Interventions

  • REGN3767 Drug
  • cemiplimab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 6, 2016
Primary completion
Apr 1, 2024
Completion
Apr 1, 2024
Last update posted
Apr 30, 2024

2016 – 2024

United States locations

U.S. sites
33
U.S. states
20
U.S. cities
31
Facility City State ZIP Site status
California Cancer Associates for Research and Excellence Encinitas California 92024
California Cancer Associates For Research And Excellence Fresno California 93720
University of California San Diego (UCSD) La Jolla California 92093-0698
The Angeles Clinic Los Angeles California 90025
University of California Davis Health Systems Sacramento California 95817
California Pacific Medical Center (CPMC) San Francisco California 94115
University of Colorado Cancer Center Aurora Colorado 80045
Lombardi Comprehensive Cancer Center - MedStar Georgetown University Hospital Washington D.C. District of Columbia 20007
Miami Cancer Institute Miami Florida 33176
Orlando Health, Inc Orlando Florida 32806
Winship Cancer Institute at Emory University Atlanta Georgia 30322
University of Kansas Clinical Research Center Fairway Kansas 66205
Dana Farber Cancer Institute Jamaica Plain Massachusetts 02130
Henry Ford Health Hospital Detroit Michigan 48202
Cancer and Hematology Centers of Western Michigan Grand Rapids Michigan 49503
Washington University in Saint Louis St Louis Missouri 63110
John Theurer Cancer Center, Hackensack University Medical Center Hackensack New Jersey 07601
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903
New Mexico Cancer Care Alliance-UNM Cancer Center Albuquerque New Mexico 87131
Roswell Park Cancer Institute Buffalo New York 14263
Northwell Health-Monter Cancer Center Lake Success New York 11042
Laura & Isaac Perlmutter Cancer Center New York New York 10016
Columbia University New York New York 10032
Memorial Sloan-Kettering Cancer Center New York New York 10065
Levine Cancer Institute Charlotte North Carolina 28204
University Hospitals Seidman Cancer Center and Case Western Reserve University Cleveland Ohio 44087
Stephenson Cancer Center Oklahoma City Oklahoma 73104
Rhode Island Hospital Providence Rhode Island 02903
Hollings Cancer Center - Medical University of South Carolina Charleston South Carolina 29425
Sarah Cannon Research Institute Nashville Tennessee 37203
The University of Texas MD Anderson Cancer Center Houston Texas 77030
South Texas Oncology and Hematology San Antonio Texas 78229
Virginia Cancer Care Specialist, PC Fairfax Virginia 22031

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03005782, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 30, 2024 · Synced May 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03005782 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →